UNSPSC 51412704: Naftidrofuryl oxalate

This classification denotes a vasodilating agent and serotonin antagonist with the molecular formula C24H33NO3.C2H2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5ADB8D9388, chemically known as 2-furanpropionic acid, tetrahydro-.alpha.-(1-naphthylmethyl)-, 2-(diethylamino)ethyl esteroxalate (1:1) but more generally known as nafronyl oxalate, which bears US NIH Compound Identifier 4417. European Medicines Agency schedules Nafronyl oxalate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20719.

Most nations, for tariff and trade purposes, schedule naftidrofuryl oxalate under HS 29321900. SMILES: CCN(CC)CCOC(=O)C(CC1CCCC2C1CCCC2)CC3CCCO3.C(=O)(C(=O)O)O.

UNSPSC 51412704 Naftidrofuryl oxalate, a Commodity code, encompasses pharmaceutical products procured by state and local health agencies, emergency services, and multi-state cooperative purchasing alliances for patient care and clinical use. Recent solicitations show state and local governments buying generic and branded pharmaceutical medications—including Advanced Life Support drugs, OTC products, and specialty therapeutics—through direct supply contracts, cooperative purchasing frameworks, and manufacturer-direct programs. Issuing bodies include city fire departments (Tampa Fire Rescue), state health and human services commissions (Texas HHS), and multi-state cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance or MMCAP), reflecting a mix of municipal emergency services, state Medicaid or pharmacy benefit programs, and regional cooperative purchasing vehicles that aggregate demand across member jurisdictions.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa issued an IFB (Bid No. 26P00188) on April 24, 2026, with a response deadline of April 8, 2026, for Advanced Life Support Medications including labetalol, epinephrine, adenosine, and diltiazem, with an estimated contract value of $40,000 and a Small Local Business Enterprise sheltered market designation offering a 5 percent bid discount. The Texas HHS Commission posted an RFI (HHS0017013) on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program aimed at improving prescription fulfillment efficiency outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, on behalf of MMCAP, issued an RFP (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through three authorized wholesalers effective July 1, 2026, with evaluation weighted 75 percent on price competitiveness and 25 percent on administrative compliance and technical capability. All solicitations require FDA compliance, Good Manufacturing Practices certification, Safety Data Sheets documentation, and expiration-date warranties.